Lesson plan
Giredestrant
Giredestrant (also known as GDC-9545, RG6171, or RO7197597) is an investigational oral selective estrogen receptor degrader (SERD) developed by Genentech, a member of the Roche Group, for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced breast cancer, as well as endometrial cancer, ovarian cancer, and other solid tumors. It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency. Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein. As of May 2025, giredestrant is in clinical trials and has received Fast Track designation from the Food and Drug Administration (FDA) for ER+, HER2-negative second- and third-line metastatic breast cancer.
Article summary
Giredestrant (also known as GDC-9545, RG6171, or RO7197597) is an investigational oral selective estrogen receptor degrader (SERD) developed by Genentech, a member of the Roche Group, for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced breast cancer, as well as endometrial cancer, ovarian cancer, and other solid tumors. It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency. Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein. As of May 2025, giredestrant is in clinical trials and has received Fast Track designation from the Food and Drug Administration (FDA) for ER+, HER2-negative second- and third-line metastatic breast cancer.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.